These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 8639793)
1. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Puri RK; Leland P; Obiri NI; Husain SR; Kreitman RJ; Haas GP; Pastan I; Debinski W Blood; 1996 May; 87(10):4333-9. PubMed ID: 8639793 [TBL] [Abstract][Full Text] [Related]
2. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. Debinski W; Obiri NI; Pastan I; Puri RK J Biol Chem; 1995 Jul; 270(28):16775-80. PubMed ID: 7622490 [TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4. Kornmann M; Kleeff J; Debinski W; Korc M Anticancer Res; 1999; 19(1A):125-31. PubMed ID: 10226533 [TBL] [Abstract][Full Text] [Related]
4. Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor alpha chain. Kawakami K; Joshi BH; Puri RK Hum Gene Ther; 2000 Sep; 11(13):1829-35. PubMed ID: 10986556 [TBL] [Abstract][Full Text] [Related]
5. Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin. Maini A; Hillman G; Haas GP; Wang CY; Montecillo E; Hamzavi F; Pontes JE; Leland P; Pastan I; Debinski W; Puri RK J Urol; 1997 Sep; 158(3 Pt 1):948-53. PubMed ID: 9258124 [TBL] [Abstract][Full Text] [Related]
6. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Husain SR; Obiri NI; Gill P; Zheng T; Pastan I; Debinski W; Puri RK Clin Cancer Res; 1997 Feb; 3(2):151-6. PubMed ID: 9815666 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Kawakami K; Kawakami M; Joshi BH; Puri RK Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072 [TBL] [Abstract][Full Text] [Related]
8. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Joshi BH; Kawakami K; Leland P; Puri RK Clin Cancer Res; 2002 Jun; 8(6):1948-56. PubMed ID: 12060640 [TBL] [Abstract][Full Text] [Related]
9. Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin. Puri RK; Debinski W; Obiri N; Kreitman R; Pastan I Cell Immunol; 1994 Apr; 154(1):369-79. PubMed ID: 8131209 [TBL] [Abstract][Full Text] [Related]
10. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. Debinski W; Miner R; Leland P; Obiri NI; Puri RK J Biol Chem; 1996 Sep; 271(37):22428-33. PubMed ID: 8798406 [TBL] [Abstract][Full Text] [Related]
11. An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity. Puri RK; Leland P; Obiri NI; Husain SR; Mule J; Pastan I; Kreitman RJ Cell Immunol; 1996 Jul; 171(1):80-6. PubMed ID: 8660841 [TBL] [Abstract][Full Text] [Related]
12. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft. Husain SR; Puri RK Blood; 2000 Jun; 95(11):3506-13. PubMed ID: 10828036 [TBL] [Abstract][Full Text] [Related]
13. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Debinski W; Obiri NI; Powers SK; Pastan I; Puri RK Clin Cancer Res; 1995 Nov; 1(11):1253-8. PubMed ID: 9815919 [TBL] [Abstract][Full Text] [Related]
14. Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells. Kawakami M; Kawakami K; Puri RK Cancer Immunol Immunother; 2002 Feb; 50(12):691-700. PubMed ID: 11862421 [TBL] [Abstract][Full Text] [Related]
15. Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells. Han J; Yang L; Puri RK J Neurooncol; 2005 Mar; 72(1):35-46. PubMed ID: 15803373 [TBL] [Abstract][Full Text] [Related]
16. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Husain SR; Joshi BH; Puri RK Int J Cancer; 2001 Apr; 92(2):168-75. PubMed ID: 11291041 [TBL] [Abstract][Full Text] [Related]
17. Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Kawakami K; Husain SR; Bright RK; Puri RK Cancer Gene Ther; 2001 Nov; 8(11):861-8. PubMed ID: 11773976 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. Husain SR; Puri RK J Neurooncol; 2003 Oct; 65(1):37-48. PubMed ID: 14649884 [TBL] [Abstract][Full Text] [Related]
19. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model. Kawakami K; Husain SR; Kawakami M; Puri RK Mol Med; 2002 Aug; 8(8):487-94. PubMed ID: 12435859 [TBL] [Abstract][Full Text] [Related]
20. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin. Kioi M; Kawakami K; Puri RK Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]